Last updated: June 6, 2026
What is VAFSEO’s FDA identity (active ingredient and application number)?
Featured answer: A supplier map requires the FDA marketing identity (active ingredient, dosage form/strength, and NDA/BLA/ANDA reference). “VAFSEO” alone is insufficient to connect to an FDA application, Orange Book listing, or labeling.
Which identifiers are needed to identify suppliers
- Active ingredient name (USAN/generic)
- Dosage form (tablet, capsule, injection, etc.)
- Strength and route of administration
- FDA application type and number (NDA/BLA) or reference product (RLD)
- Labeler name(s) and manufacturer-of-record on the FDA label
Which companies supply VAFSEO’s active pharmaceutical ingredient (API)?
Featured answer: Not determinable without the API identity and FDA labeling/manufacturer-of-record fields.
What supplier lines typically appear in sourcing workflows
- API manufacturer (DMF holder and site list)
- API intermediates suppliers (where disclosed in DMFs and regulatory filings)
- Sterile fill-finish supplier (if injection or ophthalmic)
- Solid dosage manufacture sites (if tablets/capsules)
- Primary packaging and secondary packaging suppliers (where stated)
Who manufactures VAFSEO as finished dosage form (CDMO and drug product sites)?
Featured answer: Not determinable without knowing the dosage form, route, and FDA label manufacturing sites.
Manufacturing risk points that affect supplier choice
- Sterility assurance and aseptic controls (injectables)
- Containment and dust control (high potency molecules)
- Analytical release testing capacity and method ownership
- Stability and shelf-life model alignment with packaging systems
What contract manufacturing organization (CMO/CDMO) supports VAFSEO?
Featured answer: Not determinable without a validated mapping from VAFSEO to FDA labeling and drug master files.
How supplier ownership is usually traced
- Drug product label “Manufactured for” and “Manufactured by”
- Facility names linked to FDA establishment listings
- DMF links for API sites
- Sponsor-customer disclosures in procurement documents and bid tenders
What is the Orange Book status of VAFSEO (and how does that affect supplier access)?
Featured answer: Not determinable without the NDA/RLD identification.
How Orange Book affects supplier and generic entry
- Listed patents and exclusivity can constrain alternative manufacturing or launch timing
- Paragraph IV challenges can drive litigation that impacts supply continuity
- Approval-to-market timing affects CMOs’ slot reservations and raw material contracts
Do biosimilars or generics exist for VAFSEO, and who are their suppliers?
Featured answer: Not determinable without confirmation whether VAFSEO is small molecule, biologic, or a branded combination, and without the FDA reference product.
Small molecule generic pathway
- ANDA filer and proposed manufacturing sites
- Patent carve-outs and design-around formulations
Biologic pathway
- BLA reference product mapping
- Biosimilar manufacturing chain and DS/DP site disclosures
What are VAFSEO’s formulation and process constraints for suppliers?
Featured answer: Not determinable without knowing the formulation type (oral solid, injectable solution, lyophilized, etc.) and any protected process steps.
Supplier constraints usually evaluated in diligence
- Particle size/crystal form control (if applicable)
- Lyophilization cycle parameters (if applicable)
- Sterile filtration and fill line compatibility (if applicable)
- Compatibility with specific container closures
Which upstream raw material suppliers affect VAFSEO continuity?
Featured answer: Not determinable without API identity and the disclosed material supply chain.
Common continuity drivers
- Single-source API intermediates
- Capacity limits at fill-finish facilities
- Packaging component supply constraints (closures, stoppers, blister film)
What supplier risks exist for VAFSEO (regulatory actions, recalls, or quality holds)?
Featured answer: Not determinable without FDA establishment mapping to specific manufacturing sites and historical enforcement records.
Risk signals used in sourcing decisions
- FDA Form 483/Warning Letters tied to relevant facilities
- Import alerts or sample testing failures
- Recalls linked to manufacturing deviations
Key Takeaways
- A supplier analysis for “VAFSEO” cannot be completed without unambiguous FDA drug identity (active ingredient, dosage form/strength, and NDA/BLA/ANDA linkage).
- Once the FDA identity is established, supplier mapping is typically built from label manufacturer-of-record, FDA DMF/establishment linkages, and Orange Book/RLD status.
FAQs
- How do I identify VAFSEO’s API supplier without the DMF?
- Where on FDA labeling can I find the manufacturer-of-record for VAFSEO?
- What steps connect an FDA application to CMOs/CDMOs for VAFSEO?
- Does VAFSEO’s exclusivity status constrain contract manufacturing for generics?
- How do FDA establishment records affect supplier due diligence for VAFSEO?
References
No sources were cited because VAFSEO’s FDA identity could not be determined from the provided information.
